KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Goodwill (2016 - 2023)

Historic Goodwill for Emergent BioSolutions (EBS) over the last 14 years, with Q2 2023 value amounting to $218.2 million.

  • Emergent BioSolutions' Goodwill fell 297.91% to $218.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $218.2 million, marking a year-over-year decrease of 297.91%. This contributed to the annual value of $218.2 million for FY2022, which is 297.91% down from last year.
  • As of Q2 2023, Emergent BioSolutions' Goodwill stood at $218.2 million, which was down 297.91% from $218.2 million recorded in Q1 2023.
  • Emergent BioSolutions' Goodwill's 5-year high stood at $268.6 million during Q3 2019, with a 5-year trough of $218.2 million in Q4 2022.
  • For the 5-year period, Emergent BioSolutions' Goodwill averaged around $249.5 million, with its median value being $266.4 million (2020).
  • Per our database at Business Quant, Emergent BioSolutions' Goodwill soared by 44671.28% in 2019 and then plummeted by 1567.3% in 2021.
  • Emergent BioSolutions' Goodwill (Quarter) stood at $266.6 million in 2019, then increased by 0.04% to $266.7 million in 2020, then fell by 15.67% to $224.9 million in 2021, then dropped by 2.98% to $218.2 million in 2022, then changed by 0.0% to $218.2 million in 2023.
  • Its last three reported values are $218.2 million in Q2 2023, $218.2 million for Q1 2023, and $218.2 million during Q4 2022.